Neurocrine Biosciences | NBIX - Custo de Mercadoria Vendida

Preço das Ações
128.89
Mudança Diária
-2.75 -2.09%
Mensal
-0.50%
Anual
41.84%
Q2 Previsão
125.37




Custo de Mercadoria Vendida Alterar Data
AbbVie USD 4.55B 757M 2025-12
Acadia Pharmaceuticals USD 26.22M 4.58M 2025-12
Agios Pharmaceuticals USD 1.88M 199K 2025-12
ALKERMES USD 46.21M 5.38M 2025-12
Alnylam Pharmaceuticals USD 267.72M 67.57M 2025-12
Amgen USD 1.79B 128M 2025-12
Biogen USD 810.1M 205.1M 2025-09
BioMarin Pharmaceutical USD 161.56M 16.62M 2025-12
Cytokinetics USD 99.23M 13.32M 2025-09
Exelixis USD 26.48M 7.91M 2025-12
Gilead Sciences USD 1.62B 50M 2025-12
Halozyme Therapeutics USD 102.15M 29.14M 2025-12
Incyte USD 121.18M 22.18M 2025-12
Ionis Pharmaceuticals USD 8M 5.66M 2025-12
Nektar Therapeutics USD 4.43M 5.3M 2024-09
Neurocrine Biosciences USD 17.6M 246.4M 2025-12
Pfizer USD 6.29B 2.12B 2025-12
Prothena USD 28.94M 11.58M 2025-09
Regeneron Pharmaceuticals USD 584.6M 63M 2025-12
Repligen USD 94.08M 5.79M 2025-12
Rigel Pharmaceuticals USD 8.03M 5.22M 2024-09
Sarepta Therapeutics USD 399.38M 247.93M 2025-12
Teva Pharmaceutical Industries USD 2.06B 120M 2025-12
Ultragenyx Pharmaceutical USD 29M 1.01M 2025-12
Vertex Pharmaceuticals USD 466M 51.2M 2025-12
Xoma 116K 112.7K 2024-06